Marksans Pharma Limited

Rs 2,000 crore

e geopolitical environment has impacted profitability, but we remain focused on our target to reach Rs 2,000 crores revenues along with margin improvement over the next couple of years. Mark Saldanha Founder, Cha

2.6%

t over the next couple of years. Mark Saldanha Founder, Chairman & Managing Director 1,072.8 + 2.6% (YoY) Revenue 9MY22 (₹ cr.) 195.2 (20.1)% (YoY) EBITDA 9MFY22 (₹ cr.) 157.2 (1.2)% (YoY) 9MFY

₹ 1,072.8

©2021 – Marksans Pharma Limited, All Rights Reserved. 4 9MFY22 Highlights Revenues EBITDA PAT ₹ 1,072.8 Cr ₹ 195.2 Cr ₹ 157.2 Cr 2.6% YoY (20.1)% YoY (510) Bps (1.2)% YoY (90) Bps EPS ₹ 3.82 (0

₹ 195.2

ns Pharma Limited, All Rights Reserved. 4 9MFY22 Highlights Revenues EBITDA PAT ₹ 1,072.8 Cr ₹ 195.2 Cr ₹ 157.2 Cr 2.6% YoY (20.1)% YoY (510) Bps (1.2)% YoY (90) Bps EPS ₹ 3.82 (0.3)% YoY Fi

₹ 157.2

mited, All Rights Reserved. 4 9MFY22 Highlights Revenues EBITDA PAT ₹ 1,072.8 Cr ₹ 195.2 Cr ₹ 157.2 Cr 2.6% YoY (20.1)% YoY (510) Bps (1.2)% YoY (90) Bps EPS ₹ 3.82 (0.3)% YoY Financial High

₹ 3.82

₹ 1,072.8 Cr ₹ 195.2 Cr ₹ 157.2 Cr 2.6% YoY (20.1)% YoY (510) Bps (1.2)% YoY (90) Bps EPS ₹ 3.82 (0.3)% YoY Financial Highlights Business Highlights New Launches ▪ Operating Revenue was ₹ 1,072

₹ 21.7

lights Business Highlights New Launches ▪ Operating Revenue was ₹ 1,072.8 cr. ; ▪ R&D spend of ₹ 21.7 cr. at 2.0% of sales in Launched new products: growth of 2.6 % as compared to ₹ 1,046.0 Cr. in

2.0%

ss Highlights New Launches ▪ Operating Revenue was ₹ 1,072.8 cr. ; ▪ R&D spend of ₹ 21.7 cr. at 2.0% of sales in Launched new products: growth of 2.6 % as compared to ₹ 1,046.0 Cr. in 9MFY21 ▪ E

2.6 %

1,072.8 cr. ; ▪ R&D spend of ₹ 21.7 cr. at 2.0% of sales in Launched new products: growth of 2.6 % as compared to ₹ 1,046.0 Cr. in 9MFY21 ▪ EBITDA at ₹ 195.2 cr. as compared to ₹ 244.2 cr. in 9M

₹ 1,046.0

D spend of ₹ 21.7 cr. at 2.0% of sales in Launched new products: growth of 2.6 % as compared to ₹ 1,046.0 Cr. in 9MFY21 ▪ EBITDA at ₹ 195.2 cr. as compared to ₹ 244.2 cr. in 9MFY21 ▪ EBITDA margins at 1

₹ 244.2

: growth of 2.6 % as compared to ₹ 1,046.0 Cr. in 9MFY21 ▪ EBITDA at ₹ 195.2 cr. as compared to ₹ 244.2 cr. in 9MFY21 ▪ EBITDA margins at 18.2% in 9MFY22 as against 23.3% in 9MFY21 9MFY22 ▪ Capex for

18.2%

Cr. in 9MFY21 ▪ EBITDA at ₹ 195.2 cr. as compared to ₹ 244.2 cr. in 9MFY21 ▪ EBITDA margins at 18.2% in 9MFY22 as against 23.3% in 9MFY21 9MFY22 ▪ Capex for 9MFY22 at ₹ 32.8 cr. ▪ EBITDA margin

“10 Group Structure Manufacturer of OTC Liquids & Ointments 450+ OTC/SKU products Manufacturer of Rx and OTC liquid products 162+ product licenses; Wholesale distributor of generic pharma Manufacturer of range of OTC & Rx products; 50+ products portfolio Plan to launch 3-4 new products in FY22 Distribution of quality generic pharma Only OTC Regional sales development across Asia (China, Japan, Singapore, Vietnam, Sri Lanka and South Korea) ©2021 – Marksans Pharma Limited, All Rights Reserved.”

“Nominal spend on medicine is expected to grow at projected CAGR of 8% to reach USD 685 billion by 2023, due to ageing population, greater focus on speciality diseases and biologics innovation.* ▪ Major focus on pain management with 30+ products ▪ Marksans’ differentiated product offering of Softgel ▪ Strong distribution channel marketing for both OTC and Rx Capsules alone has market potential of USD 9 billion in US** products.”

“CAGR of 3.6% to ~USD 34.0 billion by 2023, driven primarily by a universal coverage, growing disease burden and ease of healthcare access.* United Kingdom (9MFY22) 454.1 (₹ Cr.) Total Revenue 2.6% Y-o-Y Growth 42.3% Contribution to Total Revenues ©2021 – Marksans Pharma Limited, All Rights Reserved.”

“continue to remain focus markets for the Company ▪ Nova is one of the leading branded and private label ▪ Increased MA filings planned in and suppliers in Australia next 2 years Overview of the market ▪ Australia’s pharmaceutical market is set to rise to USD 28.8 billion by 2026 registering a CAGR of 2.1%* ▪ Tie-ups with topmost retailers & pharmacies in Australia, like Woolworths Ltd., Coles Mayer Ltd., Aldis, Metcash and Fauldings.”

“Overview of the market ▪ Spending in emerging markets is expected to grow at ~5% CAGR to reach USD 475 billion by 2024* Rest of the World (9MFY22) 46.5 (₹ Cr.) Total Revenue (5.0)% 4.3% Y-o-Y Growth Contribution to Total Revenues ©2021 – Marksans Pharma Limited, All Rights Reserved.”

Launched new products

1

Business

1

For more information please contact

1

Launched new products

growth of 2.6 % as compared to ₹ 1,046.0 Cr. in 9MFY21 ▪ EBITDA at ₹ 195.2 cr. as compared to ₹ 244.2 cr. in 9MFY21 ▪ EBITDA margins at 18.2% in 9MFY22 as against 23.3% in 9MFY21 9MFY22 ▪ Capex for 9MFY22 at ₹ 32.8 cr. ▪ EBITDA margin reduction due to increased input & freight costs and incremental R&D expenses ▪ Cetirizine Hydrochloride Tablets 5 mg and 10mg for perennial allergic rhinitis treatment in US ▪ Acetaminophen Extended-Release Tablets USP, 650 mg (OTC) in US ▪ Better product mix, lower depreciation , ▪ Fluoxetine in US ▪ PAT stood at ₹ 157.2 Cr. as compared to ₹159.2 Cr. in 9MFY21 finance cost and reduced tax outflow meant a marginal reduction in PAT ▪ Loperamide 2mg Hard Capsules in UK ▪ EPS for 9MFY22 was ₹ 3.82 compared to ₹3.83 in 9MFY21 ©2021 – Marksans Pharma Limited, All Rights Reserved. 5 Financial Highlights – Profit and Loss Statement Particulars (₹ cr.) 9MFY22 9MFY21 YoY Q3FY22 Q2FY22 Q3FY21 YoY Operating Revenue 1,072.8 1,046.0 2.6% 362.6 361.2 358.5 1.2% Gross

Business

Regulated Markets Focus Regulated markets: ₹ 741.6 crs Emerging markets: ₹ 32.9 crs Regulated markets: ₹ 1313.8 crs Emerging markets: ₹ 62.3 crs Products 100+ ~300 Manufacturing Facilities R&D Financials Goa: 6 billion capsules and tablets p.a. UK: 13.6 million bottles p.a. 7.8 million tubes p.a. 5.75 million units p.a. Goa: 8 billion capsules and tablets p.a. UK: 2 billion bottles p.a. 1 billion tubes p.a. 1 billion sachets p.a. USA: 5 billion tablets & capsules p.a. USA: 6 billion tablets & capsules p.a. 1- Goa R&D to sales: 0.6% Revenue: ₹ 767.2 cr. EBITDA: ₹ 44.7 cr. EBITDA %: 5.8% PAT: ₹ 11.3 Cr. 1 - Goa 2- Navi Mumbai R&D to sales: 1.4% Revenue: ₹ 1376.2 cr. EBITDA: ₹ 339.6 cr. EBITDA%: 17.2% PAT: ₹ 238.5 cr. ©2021 – Marksans Pharma Limited, All Rights Reserved. 19 ...with consistent financial performance over the years… Operating Revenue (₹ cr.) Gross Profit (₹ cr.) & Gross Profit Margin (%) 912.7 1,000.1 767.2 1,376.2 1,134.2 1,500.0 1,000.0 500.0 0.0 50.2% 49.9% 56.8% 781.1 50

For more information please contact

Investor Relations Team Jitendra Sharma (CFO) Marksans Pharma Ltd Tel: +91 022 40012000 Ravi Udeshi/ Rahul Thakur Corporate Office Christensen Investor Relations Tel : +91 22 4215 0210 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India jitendra@marksanspharma.com rudeshi@christensenir.com rthakur@christensenir.com © 2020 Marksans Pharma Limited, All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos ment